These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32347142)

  • 21. Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study.
    Sørensen JB; Horvat P; Rosenlund M; Kejs AM; Patel D; Juarez-Garcia A; Lacoin L; Daumont MJ; Penrod JR; O'Donnell JC; Brustugun OT; Ekman S
    Future Oncol; 2022 Jan; 18(2):205-214. PubMed ID: 34784783
    [No Abstract]   [Full Text] [Related]  

  • 22. Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Tanaka F; Yokomise H; Soejima T; Uramoto H; Yamanaka T; Nakagawa K; Yamamoto N; Nishimura Y; Niwa H; Okada M; Nakagawa T; Yamashita M
    Ann Thorac Surg; 2018 Oct; 106(4):1018-1024. PubMed ID: 29890150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physician preferences for management of patients with stage IIIA NSCLC: impact of bulk of nodal disease on therapy selection.
    Tanner NT; Gomez M; Rainwater C; Nietert PJ; Simon GR; Green MR; Silvestri GA
    J Thorac Oncol; 2012 Feb; 7(2):365-9. PubMed ID: 22237260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.
    Tieu BH; Sanborn RE; Thomas CR
    Thorac Surg Clin; 2008 Nov; 18(4):403-15. PubMed ID: 19086609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer.
    Yang CF; Adil SM; Anderson KL; Meyerhoff RR; Turley RS; Hartwig MG; Harpole DH; Tong BC; Onaitis MW; D'Amico TA; Berry MF
    Eur J Cardiothorac Surg; 2016 Jun; 49(6):1607-13. PubMed ID: 26719403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of mediastinal lymph node status and relapse pattern in clinical stage IIIA non-small cell lung cancer patients treated with neoadjuvant chemotherapy versus upfront surgery: A single center experience.
    Savic M; Kontic M; Ercegovac M; Stojsic J; Bascarevic S; Moskovljevic D; Kostic M; Vesovic R; Popevic S; Laban M; Markovic J; Jovanovic D
    Thorac Cancer; 2017 Sep; 8(5):393-401. PubMed ID: 28671758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trimodality vs Chemoradiation and Salvage Resection in cN2 Stage IIIA Non-Small Cell Lung Cancer.
    Ye JC; Ding L; Atay SM; Nieva JJ; McFadden PM; Chang E; Kim AW
    Semin Thorac Cardiovasc Surg; 2020; 32(1):153-159. PubMed ID: 31220530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer.
    Noh JM; Ahn YC; Lee H; Pyo H; Kim B; Oh D; Park H; Lee E; Park K; Ahn JS; Ahn MJ; Sun JM
    Cancer Res Treat; 2015 Oct; 47(4):645-52. PubMed ID: 25687864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy and Potential Application of Neoadjuvant Chemotherapy in Patients with IIIa Stage Non-small Cell Lung Cancer].
    Tang C; Qin S; Wu W; Wu Y; Zhang T
    Zhongguo Fei Ai Za Zhi; 2017 Feb; 20(2):100-106. PubMed ID: 28228221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer.
    Takeda S; Maeda H; Okada T; Yamaguchi T; Nakagawa M; Yokota S; Sawabata N; Ohta M
    Eur J Cardiothorac Surg; 2006 Jul; 30(1):184-9. PubMed ID: 16730452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal Surgical Timing After Neoadjuvant Therapy for Stage IIIa Non-Small Cell Lung Cancer.
    Rice JD; Heidel J; Trivedi JR; van Berkel VH
    Ann Thorac Surg; 2020 Mar; 109(3):842-847. PubMed ID: 31756320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer.
    Lee J; Kim HK; Park BJ; Cho JH; Choi YS; Zo JI; Shim YM; Pyo H; Ahn YC; Ahn JS; Ahn MJ; Park K; Kim J
    Lung Cancer; 2018 Jan; 115():89-96. PubMed ID: 29290268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical benefit of neoadjuvant chemoradiotherapy for the avoidance of pneumonectomy; assessment in 12 consecutive centrally located non-small cell lung cancers.
    Misumi K; Harada H; Tsubokawa N; Tsutani Y; Matsumoto K; Miyata Y; Yamashita Y; Okada M
    Gen Thorac Cardiovasc Surg; 2017 Jul; 65(7):392-399. PubMed ID: 28432576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).
    Kocher F; Pircher A; Mohn-Staudner A; Romeder F; Duller W; Steinmaurer M; Eckmayr J; Schmid T; Hilbe W; Fiegl M; Greil R
    Lung Cancer; 2014 Sep; 85(3):395-400. PubMed ID: 25043642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer.
    Sher DJ; Fidler MJ; Liptay MJ; Koshy M
    Lung Cancer; 2015 Jun; 88(3):267-74. PubMed ID: 25862147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Re: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non small-cell lung cancer.
    Leo F; De Pas T; Catalano G; Piperno G; Curigliano G; Solli P; Veronesi G; Petrella F; Spaggiari L
    J Natl Cancer Inst; 2007 Aug; 99(15):1210; author reply 1210-1. PubMed ID: 17652281
    [No Abstract]   [Full Text] [Related]  

  • 37. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.
    Friedel G; Budach W; Dippon J; Spengler W; Eschmann SM; Pfannenberg C; Al-Kamash F; Walles T; Aebert H; Kyriss T; Veit S; Kimmich M; Bamberg M; Kohlhaeufl M; Steger V; Hehr T
    J Clin Oncol; 2010 Feb; 28(6):942-8. PubMed ID: 20100967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR).
    Reymen B; van Baardwijk A; Wanders R; Borger J; Dingemans AM; Bootsma G; Pitz C; Lunde R; Geraedts W; Lambin P; De Ruysscher D
    Radiother Oncol; 2014 Mar; 110(3):482-7. PubMed ID: 24444527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgery for patients with persistent pathological N2 IIIA stage in non-small-cell lung cancer after induction radio-chemotherapy: the microscopic seed of doubt.
    Meacci E; Cesario A; Cusumano G; Lococo F; D'Angelillo R; Dall'armi V; Margaritora S; Granone P
    Eur J Cardiothorac Surg; 2011 Sep; 40(3):656-63. PubMed ID: 21402479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant chemoradiotherapy followed by surgery for stage IIIa and IIIb non-small-cell lung cancer (NSCLC): is it still justified?
    Mirimanoff RO
    Chin Clin Oncol; 2015 Dec; 4(4):49. PubMed ID: 26730761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.